IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare bleeding disorder in phase 3 trial
Disease control OngoingThis study tested an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants received either the drug or a placebo twice dail…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated May 17, 2026 04:36 UTC
-
ITP drug study halted before it began
Disease control TerminatedThis study was designed to test an experimental drug called HMPL-523 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The goal was to see if the drug is safe and can raise platelet counts. However, th…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Could a licorice root extract boost standard ITP therapy?
Disease control OngoingThis study tests whether adding diammonium glycyrrhizinate (a compound from licorice root) to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causi…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
Ongoing access to experimental ITP drug for japanese patients
Disease control OngoingThis study offers continued treatment with the oral drug rilzabrutinib to adults with chronic immune thrombocytopenia (ITP) who have already completed a long-term extension study in Japan. Only 4 participants who showed meaningful benefit and acceptable safety are eligible. The m…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC